You are here: Industry Insights > NSCLC

News List

Lilly Receives FDA Approval for Treatment of RET-Driven Lung and Thyroid Cancers americanpharmaceuticalreview
May 14, 2020
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules).
Lilly receives US FDA approval for Retevmo pharmaceutical-business-review
May 13, 2020
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) approved Retevmo (selpercatinib, 40 mg & 80 mg capsules).
FDA approves Tabrecta for treatment of metastatic non-small cell lung cancer europeanpharmaceuticalreview
May 12, 2020
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
Lilly secures FDA approval for Retevmo to treat lung/thyroid cancers pharmaceutical-technology
May 12, 2020
Eli Lilly has secured accelerated approval from the US Food and Drug Administration (FDA) for the use of Retevmo (selpercatinib) to treat lung and thyroid cancers.
FDA Grants Accelerated Approval to Capmatinib for Metastatic NSCLC americanpharmaceuticalreview
May 11, 2020
The Food and Drug Administration (FDA) granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC).
Novartis gets FDA nod for Tabrecta to treat metastatic NSCLC with METex14 pharmaceutical-business-review
May 11, 2020
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Tabrecta (capmatinib) to treat adult patients metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14).
US FDA approves Retevmo for lung, thyroid cancers with certain genetic mutations expresspharma
May 11, 2020
It is the first therapy approved specifically for cancer patients with the RET gene alterations.
Speedy US approval for Novartis' Tabrecta pharmatimes
May 07, 2020
Novartis' Tabrecta (capmatinib, formerly INC280) has been awarded accelerated approval by the US Food and Drug Administration for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET ex
FDA approves first targetted therapy to treat aggressive form of lung cancer expresspharma
May 07, 2020
The FDA also approved the FoundationOne CDx assay (F1CDx) as a companion diagnostic for Tabrecta.
Phase III Lung Cancer Trial Stopped Early Due to Significant Survival Improvement americanpharmaceuticalreview
April 29, 2020
Regeneron and Sanofi announced the primary endpoint of overall survival (OS) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® (cemiplimab).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page